ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Alpharma Yields To Takeover By King

by Rick Mullin
December 1, 2008 | APPEARED IN VOLUME 86, ISSUE 48

Alpharma has agreed to be acquired by King Pharmaceuticals in a stock deal valued at $1.6 billion. The agreement follows a series of offers by King that Alpharma CEO Dean J. Mitchell rejected, claiming they undervalued his company. In September, King took its bid directly to shareholders, upping the offer from $33 per share to $37. With 73% of shares tendered, Alpharma has now officially backed the deal. "The transformation of Alpharma over the past two years has created tremendous shareholder value, and we have consistently said we will act in the best interest of shareholders," Mitchell says.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment